Optimizing Care for Patients with Muscle Invasive Bladder Cancer (MIBC)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Wednesday 11th, March 2026
External Deadline: Tuesday 17th, March 2026
Description
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
Date RFP Issued: January 8, 2026
Geographic Scope: Canada
Clinical Area: Oncology – Genitourinary – Bladder
Link to full RFP: Optimizing Care for Patients with Muscle Invasive Bladder Cancer (MIBC)
Application Due Date: March 17, 2026
Specific Area of Interest: This RFP seeks solutions for the optimization of care of patients with muscle invasive bladder cancer (MIBC). Ideally, these projects will address important care gaps to facilitate the integration of perioperative treatments, have shortterm impact, have the ability to benefit community clinical practices, and/or involve multi-institution collaborations. This may include, but is not limited to solutions for:
- – Reducing waiting times in the MIBC patient journey
- – Developing clear and efficient referral pathways in patients diagnosed with MIBC
- – Implementing flexible multidisciplinary care models in low-resource settings, either within a single institution or through collaborative multiinstitutional partnerships
- – Optimizing patients before cystectomy (health, lifestyle)
Establishing non-MD-led adverse events (AE) management clinics (the physician is involved, but the clinic is managed by another healthcare professional)
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Ying Ying (Elena) Huang, Grant Officer (yingying.huang@pfizer.com).